KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire Substantially all the assets in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million on June 23, 2023. The consideration will be paid through the issuance of 10,000,000 Class A shares in the share capital of KDA Group. ZoomMed Board of Directors has unanimously approved an agreement for the sale. The transaction will be completed following the satisfaction or waiver of all closing conditions provided for in the asset purchase agreement, including the approval by the shareholders of the ZoomMed and obtaining the approvals from applicable regulatory authorities. As of July 28, 2023, The Transaction is effective as of July 28, 2023, and subject to the final approval from the TSX Venture Exchange. KDA and ZoomMed are arm?s length parties and no finder?s fee is payable in connection with the Transaction. On July 25, 2023, the shareholders of ZoomMed were approved the transaction.

KDA Group Inc. (TSXV:KDA) completed the acquisition of Substantially all the assets in the ZRx Prescriber from ZoomMed Medical Inc. on July 28, 2023.